Market: NMS |
Currency: USD
Address: 6555 Carnegie Avenue
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.
Show more
📈 Abeona Therapeutics Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$19.57
-
Upside/Downside from Analyst Target:
279.29%
-
Broker Call:
12
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
25-50%
-
Revenue Growth Range (1Y):
<0%
-
Upcoming Earnings Date:
2026-05-14
-
EPS Estimate:
-0.39
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Abeona Therapeutics Inc.
| Date | Reported EPS |
|---|
| 2026-05-14 (estimated upcoming) | - |
| 2026-03-17 | -0.37 |
| 2025-11-12 | -0.11 |
| 2025-08-14 | -0.47 |
| 2025-05-15 | -0.24 |
| 2025-03-20 | -0.32 |
| 2024-11-14 | -0.63 |
| 2024-08-12 | -0.44 |
| 2024-05-15 | -0.52 |
| 2024-03-18 | -0.48 |
| 2023-11-13 | -0.43 |
| 2023-08-08 | -0.5 |
| 2023-05-11 | -0.67 |
| 2022-11-14 | -1.48 |
| 2022-08-11 | -2.08 |
| 2022-05-13 | -3.5 |
| 2022-03-31 | -11.25 |
| 2021-11-15 | -3.52 |
| 2021-07-28 | -4 |
| 2021-05-17 | -4.25 |
| 2021-03-24 | -4.25 |
| 2020-11-09 | -2 |
| 2020-08-10 | -3.5 |
| 2020-05-06 | -4.11 |
| 2020-03-16 | -7.5 |
📰 Related News & Research
🔍 View more Reports
